ArticleClinical and experimental immunology2009
Toxoplasma gondii infection blocks the development of allergic airway inflammation in BALB/c mice.
Article in Clinical and experimental immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- A major Toxoplasma serine protease inhibitor protects the parasite against gut-derived serine proteases and NETosis damage.The Journal of biological chemistry · 2025Article
- The association between Toxoplasma gondii infection and asthma in the United States: A cross-sectional survey analysis.PloS one · 2025Article
- The opposing effect of acute and chronic Toxoplasma gondii infection on tumor development.Parasites & vectors · 2024Article
- Understanding Asthma and Allergies by the Lens of Biodiversity and Epigenetic Changes.Frontiers in immunology · 2021Review
- Reduction of Allergic Lung Disease by Mucosal Application ofFrontiers in immunology · 2020Article
- Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model.Pharmacology research & perspectives · 2019Article
- Article
- Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation.Scientific reports · 2017Article
- Toxoplasma gondii serine-protease inhibitor-1: A new adjuvant candidate for asthma therapy.PloS one · 2017Article
- Induction of IL-10-producing regulatory B cells followingBiochemistry and biophysics reports · 2016Article
- Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy.PloS one · 2016Article
- Toxoplasma gondii Infection Suppresses House Dust Mite Extract-Induced Atopic Dermatitis in NC/Nga Mice.Allergy, asthma & immunology research · 2015Article
- Pulmonary exposure to single-walled carbon nanotubes does not affect the early immune response against Toxoplasma gondii.Particle and fibre toxicology · 2012Article
- The effect of single and multiple infections on atopy and wheezing in children.The Journal of allergy and clinical immunology · 2012Article
- Toxoplasma gondii infection induces suppression in a mouse model of allergic airway inflammation.PloS one · 2012Article
- Harnessing regulatory T cells to suppress asthma: from potential to therapy.American journal of respiratory cell and molecular biology · 2010Review
- Antibody and cytokine responses to house dust mite allergens and Toxoplasma gondii antigens in atopic and non-atopic Brazilian subjects.Clinical immunology (Orlando, Fla.) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a link between increased allergy and a reduction of some infections in western countries. Epidemiological data also show that respiratory allergy is less frequent in people exposed to orofaecal and foodborne microbes such as Toxoplasma gondii. Infection with T. gondii induces a strong cell-mediated immunity with a highly polarized T helper type 1 (Th1) response in early stages of infection. Using a well-known murine model of allergic lung inflammation, we sought to investigate whether T. gondii infection could modulate the susceptibility to develop respiratory allergies. Both acute and chronic infection with T. gondii before allergic sensitization resulted in a diminished allergic inflammation, as shown by a decrease in bronchoalveolar lavage (BAL) eosinophilia, mononuclear and eosinophil cell infiltration around airways and vessels and goblet cell hyperplasia. Low allergen-specific immunoglobulin (Ig)E and IgG1 and high levels of allergen-specific IgG2a serum antibodies were detected. A decreased interleukin (IL)-4 and IL-5 production by lymph node cells was observed, while no antigen-specific interferon-gamma increase was detected. Higher levels of the regulatory cytokine IL-10 were found in BAL from infected mice. These results show that both acute and chronic parasite infection substantially blocked development of airway inflammation in adult BALB/c mice. Our results support the hypothesis that T. gondii infection contributes to protection against allergy in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.